Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.

Inclusion Criteria: 1. Age 18\~80 years old (inclusive), regardless of gender. 2. Voluntary written informed consent. 3. Migraine diagnosed by neurologists/pain specialists according to the current International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria for migraine with or without aura. 4. Migraine attack frequency of no less than 4 days per month within one month prior to enrollment. 5. History of pharmacotherapy for migraine prophylaxis or treatment for at least 6 months. Exclusion Criteria: 1. Findings on cerebral angiography indicating secondary headache due to intracranial vascular disorders, including dural arteriovenous fistula, arteriovenous malformation, venous malformation, or other relevant cerebrovascular lesions; Moyamoya disease; or high-risk vascular anatomical variants unsuitable for safe vascular access or contraindicating MMA embolization. 2. Complicated with cervical spondylosis and secondary headache of otogenic, rhinogenic, odontogenic origin; patients with a history of trigeminal autonomic cephalalgias; headache with other definite etiologies or secondary headache; 3. Imaging diagnosis shows acute or chronic subdural hematoma, other acute intracranial lesions and other space-occupying lesions; 4. Patients planning to undergo surgery within 90 days; 5. Patients with a life expectancy of less than 12 months; 6. Patients with a definite history of contrast media allergy; 7. Patients with a history of opioid addiction; 8. Breastfeeding or pregnant women, or patients with fertility plans within half a year; 9. Subjects who participated in other clinical trials of drugs or medical devices before enrollment and did not reach the time limit of the primary study endpoint; 10. Unable to understand headache-related assessment data such as headache diaries and requiring assistance from others to complete them; 11. Patients with poor compliance judged by the investigator and unable to complete the study as required; 12. Patients with a definite history of allergy to embolization materials such as nitinol alloy and/or cobalt-based alloy, platinum-tungsten alloy, etc.; 13. Subjects with other comorbidities that restrict their participation in the study, prevent compliance with follow-up, or affect the scientific integrity of the study; 14. Other conditions in which the investigator considers the patient inappropriate to participate in this study.